Shares of Biogen Idec (BIIB) moved higher in midday trading Friday, a day after the firm raised its offer for Facet Biotech (FACT) to $17.50 a share from $14.50 a share. Full Article at Investor's Business Daily

California-based Facet (NASDAQ: FACT) asked shareholders to take no action on the Biogen (NASDAQ: BIIB) offer, which expires Dec. 16. Biogen is based in Cambridge, Mass. Full Article at Boston Business Journal

Redwood City-based Facet (NASDAQ: FACT) asked shareholders to take no action on the Biogen (NASDAQ: BIIB) offer, which expires Dec. 16. Full Article at San Jose Business Journal

Welcome to Deal Stocks. The stocks in the news Friday are American International Group Inc. (NYSE:AIG), Kraft Foods Inc. (NYSE:KFT), Cadbury plc (NSYE:CBY), Goldman Sachs Group Inc. (NYSE:GS), Biogen Idec (NASDAQ:BIIB), Citigroup Inc. Full Article at DealScape

Biogen Idec Inc. has made a new gambit in its three-month-old hostile takeover bid for California-based Facet Biotech Corp. , which has partnered with Biogen since 2005 on joint development of a Multiple Sclerosis drug target and a treatment for solid... Full Article at Mass High Tech Business News

Today Eleanor Malone Biogen Idec has raised by 21% its offer for Facet Biotech, 13 days before its extended hostile tender offer was due to expire. Full Article at Scrip News

04 December 2009 Biogen Idec has upped its bid to acquire Facet Biotech Corp from $14.50 to $17.50 per share and is confident a takeover can now take place. Full Article at PharmaTimes

The bid represents an increase of $3, or 21 percent, over Biogen’s initial unsolicited offer on Sept. 4, Biogen said yesterday. Biogen took its bid directly to stockholders after a cash proposal was rejected by Facet’s board on Sept. 8. Full Article at Boston Globe

NEW YORK (AP) — Biogen Idec Inc . said Thursday it raised its offer for Facet Biotech Corp. to $17.50 per share from $14.50 per share, valuing Facet at a total of $493 million.The new price, which Biogen called its "best and final offer," represents a... Full Article at Newsday

This press release contains forward-looking statements of Facet Biotech that are not historical facts. These forward-looking statements may be identified by words such as "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," Full Article at Street Insider

Biogen Idec Inc. Full Article at Street Insider

* Biogen new offer is "best and final" BOSTON, Dec 3 (Reuters) - Biogen Idec Inc (BIIB.O) said on Thursday it raised its offer to buy Facet Biotech Corp to $17.50 a share from $14.50 a share, saying the new bid represents its "best and final" offer. Full Article at Reuters

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Biogen Idec Inc. Full Article at Freshnews.com

The bid represents an increase of $3, or 21 percent, over Biogen’s initial unsolicited offer on Sept. 4, Biogen said today in a statement. Biogen took its bid directly to stockholders after a cash proposal was rejected by Facet’s board on Sept. 8. Full Article at Bloomberg.com

2009-12-03 13:48:49 - Biogen Idec Inc-Financial Company Report - a new market research report on companiesandmarkets.com total common shares outstanding. Finally the report includes quarterly book value per share vs. share price. Full Article at PR-Inside.com

Today Asher Mullard Please Login to read the full article. Full Article at Scrip News

Main Category: Multiple Sclerosis Article Date: 02 Dec 2009 - 0:00 PST email to a friend printer friendly view / write opinions rate article Best-practice recommendations for the selection and management of patients with multiple sclerosis (MS)... Full Article at Medical News Today

Longer-lasting -- times 3 Just like those guys who won't spit out their Stride gum, drugmakers love extended-release formulas of their drugs. Long-lasting versions usually have higher sales because patients prefer to take drugs less frequently. Full Article at The Money Times

A Biogen Idec shareholder is castigating CEO James Mullen (photo) for selling $85 million in company stock and picking up $63 million in compensation, Reuters reports. And no, the shareholder isn't Carl Icahn. Full Article at FiercePharma